NanoPhoria Secures $98M Series A to Advance Novel Heart Failure Treatment
Key Insights
NanoPhoria Bioscience (search) raised €83.5 million ($98 million) in Series A funding led by XGEN Venture (search), Sofinnova Partners (search), and CDP Venture Capital (search) to advance heart failure treatment development.
The company's lead candidate NP-MP1 is a first-in-class peptide targeting cardiac L-type calcium channels to enhance ejection fraction in patients with heart failure with reduced ejection fraction (HFrEF).
NP-MP1 utilizes innovative lung-to-heart nano-in-micro delivery technology that has demonstrated promising results in preclinical heart failure models.
Italy-based biotech company NanoPhoria Bioscience (search) has announced the initial closing of its Series A funding round, raising €83.5 million ($98 million) to advance development of its innovative heart failure treatment. The round was led by XGEN Venture (search), Sofinnova Partners (search) and CDP Venture Capital (search), with participation from Panakès Partners (search) and an undisclosed investor.
Novel Approach to Heart Failure Treatment
NanoPhoria will use the funds to advance development of its lead candidate, NP-MP1, aimed at treating heart failure with reduced ejection fraction (HFrEF). The first-in-class peptide targets cardiac L-type calcium channels with the intention of enhancing ejection fraction for individuals with HFrEF.
The peptide is delivered through the company's proprietary lung-to-heart nano-in-micro technology, which has shown promising results in preclinical models of heart failure. This innovative delivery platform allows targeting of previously inaccessible cellular targets in the cardiomyocyte.
Clinical Development Strategy
The proceeds will be utilized for investigational new drug (IND)-enabling trials and early clinical development of NP-MP1. The funds will also support manufacturing scale-up to meet good manufacturing practice standards and help navigate the regulatory landscape.
"This financing is a transformational milestone for NanoPhoria," stated co-founder and CEO Claudio De Luca. "It enables us to accelerate clinical development of NP-MP1 and expand our pipeline. Our innovative delivery platform allows us to target previously inaccessible cellular targets in the cardiomyocyte, thereby bringing us closer to delivering life-changing treatments for patients living with serious cardiac and other chronic conditions who are underserved by existing treatments."
Technology Platform
NanoPhoria, founded in 2022, emerged from Italy's National Research Council. The company's research focuses on the development of tissue-directed delivery platform for therapeutic peptides and RNAs, using inorganic calcium-phosphate nanoparticles as a biomimetic nano-carrier.
This technology enables the targeted delivery of biologics and can be adapted for various administration methods, including inhalation. The platform's versatility positions the company to potentially address multiple therapeutic areas beyond cardiovascular disease.